Ruianto ? Cinacalcet Hydrochloride Tablets

Selected Varieties of the 5th National l Volume-Based Procurement

National Essential Drugs, Medicare Category B

[Drug Name]

       Generic Name: Cinacalcet Hydrochloride Tablets

[Indications]

        This product is used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving maintenance dialysis.

[Usage and Dosage]

       This product is for oral use. The initial adult dose is 25 mg once daily. It should be taken with food or shortly after a meal. Tablets must be swallowed whole and should not be split before use. Based on adequate monitoring of intact parathyroid hormone (iPTH), serum calcium, and serum phosphorus levels, the dose may be gradually increased from 25 mg to 75 mg once daily. If hyperparathyroidism is not adequately controlled, the maximum daily dose is 100 mg. Dose increments should be in steps of 25 mg at intervals of no less than 3 weeks.

[Contraindications]

       Contraindicated in patients with hypersensitivity to this product or any of its components. For detailed information on adverse reactions and precautions, please refer to the Chinese package insert.

[Specification]

       25 mg (calculated as C22H22F3N)

[Validity Period]

       36 months

[Approval Number]

       National Medical Approval Number: H20213175

Consultation hotline: +86 591 83512959